

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
17 April 2003 (17.04.2003)

PCT

(10) International Publication Number
WO 03/030784 A1

(51) International Patent Classification⁷:

A61F 2/06

(21) International Application Number:

PCT/US02/24037

(22) International Filing Date:

30 July 2002 (30.07.2002)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

09/974,653 10 October 2001 (10.10.2001) US

(71) Applicant: SCIMED LIFE SYSTEMS, INC. [US/US];
One Scimed Place, Maple Grove, MN 55311-1566 (US).

(72) Inventors: BICEK, Andrew, D.; 18953 113th Street S.E.,
Big Lake, MN 55309 (US). GIRTON, Timothy, S.; 15082
75th Avenue N., Maple Grove, MN 55311 (US).

(74) Agents: BUDZYN, Ludomir, A. et al.; Hoffmann &
Baron, LLP, 6900 Jericho Turnpike, Syosset, NY 11791
(US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN,
YU, ZA, ZM, ZW.


(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK,
TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: STENT DESIGN WITH SHEATH ATTACHMENT MEMBERS



WO 03/030784 A1

(57) Abstract: A stent is provided having attachment members (18) for allowing attachment of a sheath (28) or sheaths. Accordingly, a practitioner is able to selectively choose a desirable sheath, such as a polymeric sleeve, a biomaterial, or a natural blood vessel, at a point-of-use and attach it to the sheath. The attachment members may be bendable tabs and/or secondary support stents.

STENT DESIGN WITH SHEATH ATTACHMENT MEMBERS**BACKGROUND OF THE INVENTION:****FIELD OF THE INVENTION:**

[0001] This invention relates to vascular stents and, more particularly, to covered vascular stents.

DESCRIPTION OF RELATED TECHNOLOGY:

[0002] In the prior art, it is known to provide a covering for an implantable vascular stent, such as that disclosed in U.S. Patent No. 5,916,264. Such covered stents or stent/grafts are used for a variety of vascular treatments, but have particular usefulness in endovascular applications to support or maintain the patency of the natural vessel. Depending on the particular needs of a patient, a specific stent/cover combination is chosen as a treatment. Generally, however, stent coverings are emplaced on the stent at a manufacturing facility. As a result, medical practitioners have been traditionally limited in their selection of a stent and covering combination to what is commercially available.

[0003] To overcome some of the deficiencies of the prior art, mountable sheaths for emplacement onto a stent have been developed which allow a practitioner to select a particular sheath and stent combination at a point-of-use, beyond the manufacturing facility. A mountable sheath is disclosed in WIPO International Publication No. WO 00/12147, the applicant of which is the same as the assignee herein. The mountable sheath is slotted to facilitate mounting onto a stent, and may be treated with a pharmaceutical agent, radioactive agent, bioactive agent, or a combination thereof. The sheath is attached and retained on the stent using compressive force, glue, a protective sheath, or socks. The compressive force is generated radially (inwardly and/or outwardly), by the sheath itself, the stent, or both. It is, however, desired to provide a simplified method of attaching and retaining the mountable sheath, as well as other sheaths, to a stent.

SUMMARY OF THE INVENTION:

[0004] The present invention provides a means for selecting and joining a particular stent configuration and a particular covering or lining for the stent to tailor the final stent/graft device to a particular patient.

[0005] With the subject invention, a stent is provided having a radially-expandable body with axial ends, wherein at least one bendable tab extends from one of the ends. The tab is formed to be bendable so as to at least partially overlap the body upon being bent. Accordingly, a sheath or cover can be concentrically arranged (internally and/or externally) of the stent, with the tab being bent into engagement with the sheath so as to provide a holding force therein.

[0006] In one aspect of the invention, a tubular stent is provided with a plurality of circumferentially spaced tabs extending from each end. The construction of the stent may be of any configuration or material known in the art.

[0007] It is preferred that the tabs be unitarily formed from or integral with the stent, such as by being laser-cut from the same stock in forming the stent. In one embodiment of the invention, the tab is connected to the stent via a single stem which allows for relative easy bending thereof. To ensure low-risk of failure (i.e., tab separation from the stent), the stem may be strengthened by forming it thicker than the stent, using known metal-working processes, or by the application of a strengthening agent, such as a coating, cladding, and the like. Alternatively, the stem may be formed thinner than the stent to enhance bendability of the tab. Furthermore, the tab is preferably formed with a non-linear shape (such as with a U-shape, V-shape, circle shape, box shape, triangular shape, rectangle shape, and so forth) so as to provide a distributed area of contact force (as opposed to point contact or line contact) upon the sheath, with the arms of the tab diverging to further enhance this effect. To ensure that the tabs maintain their bent sheath-engagement positions during use, the tabs are preferably formed from a deformable material with little recoil or elasticity, such as stainless steel, tantalum, niobium, or a platinum-enhanced alloy.

[0008] The sheath may be formed from a polymer sleeve such as a PTFE, ePTFE, polyurethane, polypropylene, polyester or other biocompatible material. In another aspect of

the invention, the polymer sleeve may be formed of a biodegradable material. Bioactive or therapeutic agents, such as drugs or biological materials may be incorporated in or on the polymeric sleeve for release subsequent to implantation. The sleeve may also be formed from a biomaterial such as elastin or collagen, or from a section of natural blood vessel (e.g., saphenous vein). With the subject invention, a physician, or other practitioner, can selectively choose the type of sheath required, as well as the type of pre-implantation treatment thereof. For example, a physician may choose to soak a polymeric sleeve in a particular therapeutic agent prior to implantation.

[0009] Once selected, the sheath may be fixed externally or internally of the stent, by disposing it concentrically therewith, and bending the tabs accordingly to engage and secure the sheath to the stent. As an alternative embodiment, multiple sheaths can be disposed internally or externally of the stent, with the tabs holding the composite structure in place. Furthermore, one or more sheaths can be simultaneously disposed internally and externally of the stent, with a portion of the tabs being bent inwardly to provide holding force for the internal sheath(s) while a portion of the tabs are bent externally to provide a holding force for the external sheath(s).

[0010] A tool may be provided for bending the tabs in assisting a practitioner.

[0011] As a second embodiment of the subject invention, one or more secondary support stents may be utilized to hold the sheath or sheaths relative to the stent. In one variation, a ring-shaped support stent, having a much shorter axial length than the main stent, may be plastically deformed (e.g. by crimping) in proximity to an end of the main stent to provide necessary holding force for the sheath(s). One or more of such support stents may be used internally and/or externally of the main stent, as required.

[0012] These and other features of the invention will be better understood through a study of the following detailed description and accompanying drawings.

BRIEF DESCRIPTION OF DRAWINGS:

- [0013] Figure 1 is a side elevational view of a stent having bendable tabs formed in accordance with the subject invention;
- [0014] Figure 2 is an enlarged view of section 2 of Figure 1;
- [0015] Figure 3 is an elevational view of the subject invention having a sheath disposed about the body of the stent;
- [0016] Figure 4 is an end elevational view of the subject invention having multiple sheaths; and,
- [0017] Figure 5 is an elevational view of a second embodiment of the subject invention using crimped support stents.

DETAILED DESCRIPTION OF THE INVENTION:

- [0018] With the subject invention, a device and method are provided for allowing practitioners to selectively choose a sheath as a covering for a stent at a point-of-use. With this versatility, a practitioner has the ability to utilize not only polymeric sheaths, but also biomaterial and natural material, and allow for such to be treated prior to implantation, such as soaking in a therapeutic agent. The subject invention may be used in the coronary vasculature, esophagus, trachea, colon, biliary tract, urinary tract, prostate and brain.
- [0019] With reference to Figures 1-4, a first embodiment of the subject invention is depicted, wherein a stent 10 is provided having a tubular body 12, a first axial end 14, and a second axial end 16. One or more bendable tabs 18 extend from the first and/or second axial ends 14, 16.

- [0020] The stent 10 may be of any stent configuration known to those skilled in the art, including those used alone or in a stent-graft arrangement. Various stent types and stent constructions may be employed in the present invention including, without limitation, self-

expanding stents and balloon expandable stents. The stents may be capable of radially contracting as well. Self-expanding stents include those that have a spring-like action which cause the stent to radially expand or stents which expand due to the memory properties of the stent material for a particular configuration at a certain temperature. Other materials are of course contemplated, such as stainless steel, platinum, gold, titanium, tantalum, niobium, and other biocompatible materials, as well as polymeric stents. The configuration of the stent may also be chosen from a host of geometries. For example, wire stents can be fastened in a continuous helical pattern, with or without wave-like forms or zigzags in the wire, to form a radially deformable stent. Individual rings or circular members can be linked together such as by struts, sutures, or interlacing or locking of the rings to form a tubular stent.

[0021] — It is preferred that the stent 10 be of the type that is etched or cut (e.g., laser cut) from a unitary cylindrical stock. Accordingly, the tabs 18 desirably may be cut from the same stock as the tubular body 12 and be formed unitarily therewith. Desirably, the tubular body 12 is radially-expandable using conventional techniques, such as balloon distension, or may be self-expanding.

[0022] — With reference to Figure 2, in one embodiment, the tabs 18 have a generally U-shape with side legs 20 which slightly diverge. With this structural configuration, the tabs 18 may distribute holding force over an area, rather than have point contact or line contact (e.g., if a single slender wire was to be used). The side legs 20 terminate in free ends 22 which are flared slightly outwardly from an open mouth 24 of the tab. It is desired to ensure that sharp edges are eliminated from the tabs 18, especially at the free ends 22 to prevent unintended puncture of the vessel. Because the tabs 18 may be located externally of an implanted stent, and in contact with a vein wall, it is desired to ensure that micromovement of the tabs will not result in any abrading damage to the vein wall. Advantageously, where the tabs 18 may be unitarily laser cut with the tubular body 12, electropolishing of the entire assembly removes all sharp edges.

[0023] — It is preferred that the tabs 18 have a shape which imparts a holding force over an area, such as a v-shape, circle shape, box shape, triangular shape, rectangular shape and so forth with the tab 18 being defined by an element outlining the shape, or being at least partially solid across the area of the tab (e.g., a solid disc). It is preferred to use a configuration other than a slender linear shape so that, as mentioned above, holding force is

distributed over an area. A flattened or deformed wire may also distribute a holding force over an area.

[0024] The tab 18 is connected to the body 12 via a stem 26 which is bendable. With unitary manufacturing of the tabs 18 and the body 12, the stem 26 will have the same thickness as other parts of the stent 10. It may be desired, however, to strengthen the stem 26 so as to reduce the likelihood of failure thereof which may result in separation of the tabs 18 from the body 12. The stem 26 may be strengthened in a variety of ways, such as: by providing additional material therein to thicken it; using known metal-working techniques; and/or providing a strengthening agent, such as a coating, cladding, or the like. The stem 26 is formed of sufficient length to allow the tab 18 to be bent thereabout to at least partially overlap the body 12. Alternatively, it may be desired to form the stem 26 thinner than surrounding portions to enhance the bendability thereof. Also, the stem 26 may be thinned to increase its cross-sectional width so as to provide a holding force over a larger area.

[0025] With reference to Figure 3, the stent 10 is covered by a sheath 28 with the tabs 18 extending from the assembly. As previously discussed, the sheath 28 may be formed from any number of materials, including synthetic or natural polymers, biomaterials, or natural materials, such as natural blood vessel (e.g., a saphenous vein). The sheath 28 may have a tubular shape, or be slitted as shown in WIPO International Publication No. WO 00/12147. The entire disclosure of WIPO International Publication No. WO 00/12147 is incorporated herein by reference herein.

[0026] As shown in Figure 3, the sheath is concentrically disposed relative to the stent 10 (as shown in Figure 3 disposed, for example, radially outwardly) and one or more of the tabs 18 are caused to be bent into engagement therewith. Accordingly, the sheath 18 is attached to the stent 10 and shall be retained relative thereto by the holding force of the tabs 18. It is desired to have the tabs 18 sufficiently bent so that the tabs 18 are recessed within, or flush with, the sheath 28. Accordingly, it is desirable that no portion of the tabs 18 shall extend outwardly from the assembly.

[0027] To ensure that the tabs 18 maintain their bent positions after application, the tabs 18 are preferably formed from a deformable material with little recoil or elasticity, such as stainless steel, tantalum, niobium, or a platinum-enhanced alloy. Shape memory alloys,

such as nitinol, can be used so long as the tabs 18 are treated to not re-gain their original unbent shape once implanted.

[0028] With reference to Figure 4, multiple sheaths 28 may be disposed externally of the stent 10. Likewise, one or more of the sheaths 28 may be disposed radially inwardly of the stent 10, with one or more of the tabs 18 being bent inwardly into engagement with the sheath(s) 28. As a further variation, one or more sheaths 28 may be simultaneously disposed internally and externally of the stent 10, with a portion of the tabs 18 being bent inwardly, and a portion of the tabs 18 being bent outwardly.

[0029] Because of the ability to apply the sheath 28 at the point-of-use, a practitioner may choose to treat the sheath 28 prior-to-implantation, such as soaking with one or more of the following therapeutic agents: anti-thrombogenic agents (such as heparin, heparin derivatives, urokinase, and PPack (dextrophenylalanine proline arginine chloromethylketone); anti-proliferative agents (such as enoxaprin, angiopeptin, or monoclonal antibodies capable of blocking smooth muscle cell proliferation, hirudin, and acetylsalicylic acid); anti-inflammatory agents (such as dexamethasone, prednisolone, corticosterone, budesonide, estrogen, sulfasalazine, and mesalamine); antineoplastic/antiproliferative/anti-miotic agents (such as paclitaxel, 5-fluorouracil, cisplatin, vinblastine, vincristine, epothilones, endostatin, angiostatin and thymidine kinase inhibitors); anesthetic agents (such as lidocaine, bupivacaine, and ropivacaine); anti-coagulants (such as D-Phe-Pro-Arg-chloromethyl keton, an RGD-peptide-containing compound, heparin, antithrombin compounds, platelet receptor antagonists, anti-thrombin antibodies, anti-platelet receptor antibodies, aspirin, prostaglandin inhibitors, platelet inhibitors and tick antiplatelet peptides); vascular cell growth promtors (such as growth factor inhibitors, growth factor receptor antagonists, transcriptional activators, and translational promtors); vascular cell growth inhibitors (such as growth factor inhibitors, growth factor receptor antagonists, transcriptional repressors, translational repressors, replication inhibitors, inhibitory antibodies, antibodies directed against growth factors, bifunctional molecules consisting of a growth factor and a cytotoxin, bifunctional molecules consisting of an antibody and a cytotoxin); cholesterol-lowering agents; vasodilating agents; and agents which interfere with endogenous vascoactive mechanisms. In addition, radioactive agents and bioactive agents may be used in various combinations, along with the therapeutic agents listed above.

[0030] The stent 10 may take any form, such as a "box car" type stent, which utilizes discrete stent elements linked together by flexible connections, such as that shown in Figure 5 of U.S. Patent No. 5,693,085. The entire disclosure of U.S. Patent No. 5,693,085 is incorporated by reference herein. With a "box car" stent, the tabs 18 will only extend from the end elements, and not the central stent elements. It is also possible to form the stent 10 with tabs extending only from one axial end 14, 16 of a tubular stent, and only one of the tabs 18 at the respective axial end 14, 16 may be required depending on the application (e.g., amount of holding force required). It is preferred to use a plurality of the tabs 18 with such tabs 18 being circumferentially evenly-spaced, such as with three tabs 18 at each axial end 14, 16 located at intervals of 120 degrees relative to the circumference of the body 12. In this manner, an even distribution of holding force can be achieved to ensure proper fixing of the sheath 28 to the stent 10.

[0031] Conventional techniques may be used to implant the stent 10/sheath 28 assembly. As a further variation, one or more barbs 19 may be formed on one or more of the tabs 18 which are formed to puncture a surrounding vessel wall upon implantation of the assembly. The barbs 19 need only be formed on the side of the tabs 18 which will be externally exposed with a completed assembly, and preferably, are formed in proximity to the free ends 22. The barbs 19 shall act to provide additional holding force for the structure at a desired location.

[0032] A hand tool (not shown) may also be provided to aid a practitioner in bending the tabs 18.

[0033] In a second embodiment of the invention, one or more ring-shaped support stents 30 replace the tabs 18 to provide holding force for the sheath 28. With reference to Figure 5, the support stents 30 generate a relative pressing force with the stent 10 (hidden from view) to hold the sheath 28 in place. As with the tabs 18, if shape memory alloys are used in forming the support stents 30, it is desired to treat the support stents 30 such that will prevent the support stents 30 from re-gaining their original shape. It is also desirable that no portion of the stent 10 come into contact with the support stents 30.

[0034] In one variation, the support stents 30 may be plastically-deformed to provide, and maintain, the necessary holding force. For example, the support stents 30 may be

crimped. The support stents 30 may be partially plastically deformed, such at discrete points or along a region, or may be wholly plastically deformed. Any plastic deformation of the support stents 30 should not interfere with the ability of the stent 10 and the sheath 28 to be implanted (i.e., interfere with the ability to radially compress and radially expand). Alternatively, the support stents 30 and/or the stent 10 may generate a radial pressing force which holds the sheath 28.

[0035] It is preferred that the support stents 30 be of limited axial length and not be coextensive with the body 12 of the stent 10. To avoid end separation of the sheath 28 from the stent 10, the support stents 30 are disposed in proximity to the axial ends 14, 16. It is possible to use only one of the support stents 30, such as at the upstream axial end 14, 16 of the stent 10 relative to blood flow. In addition, as shown in dashed lines, it is possible to form at least one tab 18 at one axial end 14, 16 in connection with the use of one or more of the support stents 30 to supplement the holding force thereof. As an alternative, a single support stent 30 may be used which extends over a major extent of the sheath 28.

[0036] The support stents 30 may be of any construction known in the art. The structure may be plastically-deformable upon being crimped radially inwardly or outwardly.

[0037] As with the first embodiment, multiple sheaths 28 may be disposed internally and/or externally, with the support stents 30 providing holding force intraluminally. If there is reliance on plastic deformation of the support stents 30, the support stents 30 may be crimped radially outwardly to hold any internally-disposed sheaths 28.

[0038] To facilitate the plastic deformation of the support stents 30, a tool (not shown) may be provided.

[0039] Various changes and modifications can be made to the present invention. It is intended that all such changes and modifications come within the scope of the invention as set forth in the following claims.




WHAT IS CLAIMED IS:

1. A stent comprising a radially-expandable body having first and second axial ends, at least one bendable tab extending from said first axial end, said tab being bendable to at least partially overlap said body for forcibly engaging a sheath.
2. A stent as in claim 1, wherein said stent is generally cylindrical.
3. A stent as in claim 1, wherein at least one bendable tab extends from said second axial end, said tab being bendable to at least partially overlap said body.
4. A stent as in claim 1, wherein a plurality of said tabs extend from said first axial end.
5. A stent as in claim 1, wherein said at least one tab has a non-linear shape.
6. A stent as in claim 1, wherein said at least one tab is unitarily formed with said body.
7. A stent as in claim 1, further comprising at least one barb extending from at least one said tab.
8. A method of preparing a covered stent for implantation, said method comprising:
providing a stent having a radially-expandable body with first and second axial ends, at least one bendable tab extending from said first axial end;
disposing a sheath in concentric arrangement with said body; and
bending at least one of said tabs into engagement with said sheath.
9. A method as in claim 8, wherein said sheath is disposed radially outwardly of said stent.
10. A method as in claim 8, wherein said sheath is disposed radially inwardly of said stent.



11. A method as in claim 8, wherein said sheath is selected from the group consisting of a polymeric sleeve, a biomaterial sleeve, and a natural blood vessel.
12. A method as in claim 11, wherein said sheath is treated with a drug selected from the group consisting of pharmaceutical agents, radioactive agents, bioactive agents, and combinations thereof.
13. A method as in claim 8, further comprising disposing a second sheath in concentric arrangement with said body.
14. A method as in claim 13, wherein said first-mentioned sheath is disposed externally of said stent, and said second sheath is disposed internally of said stent.
15. A method as in claim 14, further comprising bending at least one of said tabs into engagement with said second sheath.
16. A method as in claim 13, wherein said second sheath is interposed between said first-mentioned sheath and said stent.
17. A covered stent comprising a main stent having a radially-expandable body, at least one support stent, and a sheath interposed between said body and said at least one support stent with no portions of said main stent being in contact with said at least one support stent.
18. A covered stent as in claim 17, wherein said at least one support stent is plastically-deformed.
19. A covered stent as in claim 17, wherein said sheath is disposed radially outwardly of said main stent.
20. A covered stent as in claim 17, wherein said sheath is disposed radially inwardly of said main stent.

21. A covered stent as in claim 17, wherein said at least one support stent has an axial length which is less than the axial length of said body.
22. A covered stent as in claim 21, wherein said at least one support stent is disposed in proximity to an end of said body.
23. A covered stent as in claim 17, wherein said sheath is selected from the group consisting of a polymeric sleeve, a biomaterial sleeve, and a natural blood vessel.
24. A covered stent as in claim 23, wherein said sheath is treated with a drug selected from the group consisting of pharmaceutical agents, radioactive agents, bioactive agents, and combinations thereof.
25. A covered stent as in claim 17, further comprising disposing a second sheath in concentric arrangement with said body.
26. A covered stent as in claim 25, wherein said first-mentioned sheath is disposed externally of said main stent, and said second sheath is disposed internally of said main stent.
27. A covered stent as in claim 26, wherein said second sheath is interposed between at least one of said support stents and said body.
28. A method of preparing a covered stent for implantation, said method comprising:
 - providing a main stent having a radially-expandable body;
 - disposing a sheath in concentric arrangement with said body; and,
 - disposing at least one support stent externally of said sheath such that said sheath is interposed between said body and said at least one support stent, and no portion of said main stent is in contact with said at least one support stent.
29. A method as in claim 28 further comprising deforming plastically said at least one support stent.

30. A method as in claim 28, wherein said sheath is disposed radially outwardly of said stent.
31. A method as in claim 28, wherein said sheath is disposed radially inwardly of said stent.
32. A method as in claim 28, wherein said sheath is selected from the group consisting of a polymeric sleeve, a biomaterial sleeve, and a natural blood vessel.
33. A method as in claim 32, wherein said sheath is treated with a drug selected from the group consisting of pharmaceutical agents, radioactive agents, bioactive agents, and combinations thereof.
34. A method as in claim 28, further comprising disposing a second sheath in concentric arrangement with said body.
35. A method as in claim 34, wherein said first-mentioned sheath is disposed externally of said main stent, and said second sheath is disposed internally of said main stent.
36. A method as in claim 34, wherein said second sheath is interposed between at least one of said support stents and said body.
37. A method as in claim 28, wherein said at least one support stent has an axial length which is less than the axial length of said body.
38. A method as in claim 37, wherein said at least one support stent is disposed in proximity to an end of said body.

**FIG. 1****FIG. 2****FIG. 3**

2/2

**FIG. 4****FIG. 5**

INTERNATIONAL SEARCH REPORT

Internat'l Application No

PCT/US 02/24037

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61F2/06

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61F

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 01 66035 A (DISENO Y DESARROLLO MEDICO S A) 13 September 2001 (2001-09-13)	1-6,8,9, 11,12 13,14 7,16,17, 28
Y		
A	page 2, line 9 - line 20 page 12, line 13 - line 21 page 12, line 22 -page 13, line 13 page 18, line 24 -page 20, line 11 figures 8-10,17-20	-/-

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

• Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

6 November 2002

Date of mailing of the international search report

14/11/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Amaro, H

INTERNATIONAL SEARCH REPORT

Inter
nal Application No
PCT/US 02/24037

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant lines
X	US 5 916 264 A (VON OEPEN RANDOLF ET AL) 29 June 1999 (1999-06-29)	17-19, 23,24, 28-30, 32,33
Y A	column 2, line 16 - line 34 figure 1	25,34 20,21, 28,31
Y A	US 5 749 880 A (BANA CHRISTOPHER E ET AL) 12 May 1998 (1998-05-12)	13,14, 25,34 17-21, 23-25, 27,35,36
	column 4, line 21 - line 44 column 12, line 20 - line 32 column 13, line 10 - line 42 column 18, line 12 - line 60 figures 1,2,7-8	
X	US 5 628 788 A (PINCHUK LEONARD) 13 May 1997 (1997-05-13)	17-19, 23,24, 28-30, 32,33
A	column 7, line 40 -column 8, line 37 column 3, line 38 - line 47 figures 8,10,11	13,20, 21,25, 28,31
A	EP 0 960 607 A (MEDTRONIC AVE INC) 1 December 1999 (1999-12-01) column 3, line 28 - line 38 column 4, line 13 -column 5, line 8 column 5, line 33 - line 46 claims 1,2,5-7 figures 1,2A	17,28, 37,38

INTERNATIONAL SEARCH REPORT

In international application No.
PCT/US 02/24037

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:

2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International search can be carried out, specifically:

3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

see additional sheet

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
- No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-16

Stent and method for preparing it for implantation comprising a radially expandable body with bendable tab elements for engaging a sheath.

2. Claims: 17-38

Covered stent and method for preparing it for implantation comprising a main stent, at least one support stent and a sheath interposed between them.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 02/24037

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
WO 0166035	A	13-09-2001	AU WO	4095601 A 0166035 A2		17-09-2001 13-09-2001
US 5916264	A	29-06-1999	DE AT CA DK EP ES GR JP JP PT	19720115 A1 195239 T 2224548 A1 878173 T3 0878173 A1 2151218 T3 3034716 T3 3211156 B2 10314313 A 878173 T		24-12-1998 15-08-2000 14-11-1998 27-12-2000 18-11-1998 16-12-2000 31-01-2001 25-09-2001 02-12-1998 30-11-2000
US 5749880	A	12-05-1998	US CA DE DE EP ES JP US US WO US US US US US ZA	6124523 A 2215027 A1 69518337 D1 69518337 T2 0814729 A1 2151082 T3 10510196 T 2002038143 A1 6004348 A 9628115 A1 2001039446 A1 2001025131 A1 2001021870 A1 6264684 B1 6383214 B1 9510700 A		26-09-2000 19-09-1996 14-09-2000 01-02-2001 07-01-1998 16-12-2000 06-10-1998 28-03-2002 21-12-1999 19-09-1996 08-11-2001 27-09-2001 13-09-2001 24-07-2001 07-05-2002 25-11-1996
US 5628788	A	13-05-1997	AU AU EP JP NO WO US US	703673 B2 7668996 A 0877581 A1 11501243 T 982052 A 9717039 A1 6348066 B1 2001044647 A1		01-04-1999 29-05-1997 18-11-1998 02-02-1999 02-07-1998 15-05-1997 19-02-2002 22-11-2001
EP 0960607	A	01-12-1999	US AU EP JP	6099559 A 3126099 A 0960607 A1 11347133 A		08-08-2000 09-12-1999 01-12-1999 21-12-1999

THIS PAGE BLANK (USPTO)